AstraZeneca PLC
Suletud
SektorTervishoid
11,732 -0.37
Ülevaade
Aktsiahinna muutus
24h
Min
11716
Max
11776
Sissetulek | -1.4B 2.5B |
|---|---|
Müük | 96M 15B |
P/E Sektori keskmine | 24.32 56.597 |
Aktsiakasum | 2.63 |
Dividenditootlus | 1.96 |
Kasumimarginaal | 16.095 |
Töötajad | 96,100 |
EBITDA | -510M 5.2B |
Dividenditootlus Sektori keskmine | 1.96% 2.18% |
|---|---|
Järgmine tulemuste avaldamine | 30. okt 2026 |
Turukapital | -9.6B 252B |
|---|---|
Eelmine avamishind | 11732.37 |
Eelmine sulgemishind | 11732 |
Uudiste sentiment
By Acuity
63%
37%
281 / 339 Pingereas Healthcare
AstraZeneca PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
AstraZeneca PLC Prognoos
Sentiment
By Acuity
281 / 339 Pingereas Tervishoid
Uudiste sentiment
Tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.